Natural course of post-COVID symptoms in adults and children
Aya Sugiyama,
No information about this author
Toshiro Takafuta,
No information about this author
Tomoki Sato
No information about this author
et al.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Feb. 16, 2024
Abstract
More
than
200
million
COVID-19
survivors
have
lasting
symptoms
after
recovering,
but
the
duration
and
related
risk
factors
remain
uncertain.
This
study
focused
on
all
6551
patients
diagnosed
with
at
a
medical
institution
in
Hiroshima
from
March
2020
to
July
2022.
In
November
2022,
questionnaire
survey
was
conducted
regarding
post-COVID
their
duration.
The
prevalence
of
were
illustrated
using
Kaplan–Meier
method.
Risk
for
over
3
months
interfering
daily
life
assessed
via
multivariate
logistic
regression.
A
total
2421
responded:
1391
adults,
1030
children,
median
age
34
years
(IQR
9–55),
51·2%
male,
36·7%
hospitalized,
time
infection
295
days
201–538).
Upon
initial
recovery,
78·4%
adults
34·6%
children.
Three
later,
rates
47·6%
10·8%.
After
one
year,
they
31·0%
6·8%.
Regarding
interfere
life,
304
people
(12.6%)
experienced
three
months,
independent
including
age,
being
female,
diabetes
mellitus,
during
Delta
period,
current
smoking.
There
no
significant
association
between
vaccination
history
symptoms.
Language: Английский
Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system
Journal of Neurology,
Journal Year:
2023,
Volume and Issue:
271(1), P. 519 - 525
Published: Oct. 3, 2023
Abstract
Background
Although
still
incomplete,
the
epidemiology
of
epilepsy
shows
substantial
variations
in
burden
condition
according
to
demographic,
social
and
territorial
characteristics.
This
study
aimed
estimate
prevalence
treated
investigate
its
demographic
spatial
distribution
2020
France,
a
country
where
nationwide
epidemiological
situation
remains
largely
unknown.
Methods
We
used
French
national
health
data
system,
which
covers
nearly
entire
population
residing
France
(over
67
million
inhabitants
metropolitan
overseas
departments).
Prevalent
cases
were
identified
using
long-term
disease
status,
hospitalisation
for
(ICD-10
codes
G40
or
G41),
reimbursements
antiseizure
medications
electroencephalograms.
Results
In
2020,
we
685,122
cases,
corresponding
an
overall
10.2
per
1000
[95%
confidence
interval
10.1–10.2],
with
similar
rates
men
women.
Estimates
found
increase
age,
accelerated
rise
second
half
life,
occurred
earlier
than
observed
monotonic
gradient
variation
socio-economic
deprivation
(in
non-military
subjects
aged
18–54
years)
as
well
heterogeneity,
mountainous
centre
some
departments
having
highest
prevalence.
Conclusions
Our
results
revise
upwards
estimation
showing
that
it
now
ranks
among
developed
countries.
also
confirms
important
socio-territorial
heterogeneity
reflects
inequalities
this
country.
Language: Английский